argenx SE (argenx SE) Change In Receivables : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Change In Receivables?

argenx SE's change in receivables for the quarter that ended in Dec. 2023 was $0 Mil. It means argenx SE's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

argenx SE's change in receivables for the fiscal year that ended in Dec. 2023 was $-186 Mil. It means argenx SE's Accounts Receivable increased by $186 Mil from Dec. 2022 to Dec. 2023 .

argenx SE's Accounts Receivable for the quarter that ended in Dec. 2023 was $418 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. argenx SE's Days Sales Outstanding for the three months ended in Dec. 2023 was 93.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. argenx SE's liquidation value for the three months ended in Dec. 2023 was $3,204 Mil.

argenx SE Change In Receivables Historical Data

The historical data trend for argenx SE's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Change In Receivables Chart

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-25.71

21.96

-31.63

-222.26

-185.69

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

argenx SE Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

argenx SE (NAS:ARGX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

argenx SE's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	417.994	/	406.837	*	91
=	93.75

2. In Ben Graham's calculation of liquidation value, argenx SE's accounts receivable are only considered to be worth 75% of book value:

argenx SE's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3179.844	-	444.951	+	0.75 * 417.994	+	0.5 * 310.55
=	3,204

argenx SE Change In Receivables Related Terms

Thank you for viewing the detailed overview of argenx SE's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.